Logo image of VCNX

VACCINEX INC (VCNX) Stock Fundamental Analysis

NASDAQ:VCNX - US9186403013 - Common Stock

1.41 USD
-2.24 (-61.37%)
Last: 12/17/2024, 9:35:36 PM
1.3211 USD
-0.09 (-6.3%)
After Hours: 12/17/2024, 9:35:36 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to VCNX. VCNX was compared to 547 industry peers in the Biotechnology industry. VCNX may be in some trouble as it scores bad on both profitability and health. VCNX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VCNX had negative earnings in the past year.
VCNX had a negative operating cash flow in the past year.
In the past 5 years VCNX always reported negative net income.
VCNX had a negative operating cash flow in each of the past 5 years.
VCNX Yearly Net Income VS EBIT VS OCF VS FCFVCNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -382.72%, VCNX is not doing good in the industry: 96.62% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -382.72%
ROE N/A
ROIC N/A
ROA(3y)-344.5%
ROA(5y)-394.42%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VCNX Yearly ROA, ROE, ROICVCNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VCNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VCNX Yearly Profit, Operating, Gross MarginsVCNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K -20K

More info and screens

0

2. Health

2.1 Basic Checks

VCNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VCNX has been increased compared to 1 year ago.
The number of shares outstanding for VCNX has been increased compared to 5 years ago.
Compared to 1 year ago, VCNX has a worse debt to assets ratio.
VCNX Yearly Shares OutstandingVCNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
VCNX Yearly Total Debt VS Total AssetsVCNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

VCNX has an Altman-Z score of -116.17. This is a bad value and indicates that VCNX is not financially healthy and even has some risk of bankruptcy.
VCNX's Altman-Z score of -116.17 is on the low side compared to the rest of the industry. VCNX is outperformed by 98.04% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -116.17
ROIC/WACCN/A
WACC10.93%
VCNX Yearly LT Debt VS Equity VS FCFVCNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

2.3 Liquidity

A Current Ratio of 0.77 indicates that VCNX may have some problems paying its short term obligations.
VCNX has a worse Current ratio (0.77) than 90.39% of its industry peers.
A Quick Ratio of 0.77 indicates that VCNX may have some problems paying its short term obligations.
VCNX's Quick ratio of 0.77 is on the low side compared to the rest of the industry. VCNX is outperformed by 90.39% of its industry peers.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.77
VCNX Yearly Current Assets VS Current LiabilitesVCNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

VCNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.54%, which is quite impressive.
The Revenue for VCNX has decreased by -51.19% in the past year. This is quite bad
Measured over the past years, VCNX shows a decrease in Revenue. The Revenue has been decreasing by -4.67% on average per year.
EPS 1Y (TTM)85.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.47%
Revenue 1Y (TTM)-51.19%
Revenue growth 3Y-3.02%
Revenue growth 5Y-4.67%
Sales Q2Q%160%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VCNX Yearly Revenue VS EstimatesVCNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
VCNX Yearly EPS VS EstimatesVCNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 -200 -400 -600 -800

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VCNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VCNX Price Earnings VS Forward Price EarningsVCNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VCNX Per share dataVCNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

VCNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VACCINEX INC

NASDAQ:VCNX (12/17/2024, 9:35:36 PM)

After market: 1.3211 -0.09 (-6.3%)

1.41

-2.24 (-61.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2024-11-11/bmo
Earnings (Next)N/A N/A
Inst Owners51.85%
Inst Owner Change0%
Ins Owners0.38%
Ins Owner Change0%
Market Cap3.78M
Analysts85.71
Price TargetN/A
Short Float %0.08%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.74
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.16
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-5.92
FCFYN/A
OCF(TTM)-5.91
OCFYN/A
SpS0.14
BVpS-0.49
TBVpS-0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -382.72%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-344.5%
ROA(5y)-394.42%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.15%
Cap/Sales 5.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.77
Altman-Z -116.17
F-Score4
WACC10.93%
ROIC/WACCN/A
Cap/Depr(3y)41.02%
Cap/Depr(5y)49.77%
Cap/Sales(3y)17.1%
Cap/Sales(5y)22.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.47%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-51.19%
Revenue growth 3Y-3.02%
Revenue growth 5Y-4.67%
Sales Q2Q%160%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.23%
OCF growth 3YN/A
OCF growth 5YN/A